Search IMCR
Immunocore Holdings plc
Nasdaq · CIK 1671927
Last close29.71
Daily change-0.83 (-2.72%)
10 Years gain-31.23%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
IMCR · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
56.9Momentum
100.0Acceleration
100.0Confidence
75.0Annual Revenue5
Quarterly Revenue11
Annual CFO5
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality14.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.2851 percentage points.
Operating leverageOperating margin improved by 12.8821 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 1.8787%.
Key Metrics
Revenue Growth TTM32.57%OK
Revenue CAGR 3Y31.89%OK
Gross Margin99.28%OK
Operating Margin-4.19%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-1.88%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $400.02M | $394.93M | -$45.35M | -$10.71M | -$15.05M | 98.73% | -11.34% | -3.76% | n/a | 50.35M |
| 2025 FY Dec 31, 2024 | $310.20M | $307.47M | -$70.46M | $26.06M | $20.89M | 99.12% | -22.71% | 6.73% | n/a | 49.99M |
| 2025 FY Dec 31, 2023 | $249.43M | $248.39M | -$59.65M | $2.94M | -$2.49M | 99.58% | -23.91% | -1% | n/a | 48.89M |
| 2024 FY Dec 31, 2022 | $174.36M | $173.27M | -$51.71M | -$49.21M | -$51.41M | 99.38% | -29.66% | -29.49% | n/a | 45.71M |
| 2023 FY Dec 31, 2021 | $4.08M | $4.08M | -$174.59M | -$143.11M | -$144.49M | 100% | -4,281.19% | -3,543.21% | n/a | 42.49M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $424.26M | sum latest 4 fiscal quarters Revenue | OK | 0001671927-26-000022, 0001671927-25-000018 |
| Revenue Growth TTM | 32.57% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001671927-26-000022, 0001671927-25-000018 |
| Revenue CAGR 3Y | 31.89% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001671927-26-000005 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001671927-26-000005 |
| Gross Profit CAGR 3Y | 31.6% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001671927-26-000005 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001671927-26-000022, 0001671927-25-000018 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 99.28% | Gross Profit / Revenue | OK | 0001671927-26-000022, 0001671927-25-000018 |
| Operating Margin | -4.19% | Operating Income / Revenue | OK | 0001671927-26-000022, 0001671927-25-000018 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001671927-26-000022 |
| Current Ratio | 4.47x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $8.32 | Revenue / Diluted Shares | OK | 0001671927-26-000022, 0001671927-25-000018 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001671927-26-000005 |